alzheimer's association®

Business Consortium

AI: Helping Early Research

Gabrielle Foster, MSPH
Founder & CEO Foster RX

AI: Helping Early Research

Alzheimer's Association Business Consortium
Gabrielle Foster, MSPH, MPH
February 25, 2026

FOSTER RX

The decision intelligence layer for clinical trial execution.

AI is working — *just not where small biotechs need it most.*

50%

of biotechs already report faster time-to-target using AI

56% expect meaningful cost reductions within 2 years

24%

AI adoption at IND stage — the lowest point in the entire pipeline

The most complex, consequential decisions have the least AI support — data quality & availability cited as #1 barrier by 55%

90%

of small biotechs rely exclusively on freely available public datasets

Large biotechs license commercial databases (71%) and real-world evidence

The Preclinical-to-Clinical Translational Gap

Most Pre-IND ALZ assets fail because they never prove value in a ***convincing***, ***measurable***, way.

- TRANSGENIC MICE HUMANS
- ENDPOINT SELECTION COMPLEXITY
- WRONG PATIENT POPULATIONS
- BIOMARKER VALIDATION ERRORS
- LACK OF DISEASE HETEROGENEITY

Insanity = repeating the same mistakes from failed trials to the tune of **billions($)**

Pre-IND clinical trials are where value is won or lost



28% of programs **complete** Phase II

90% of Phase II's have **>1 substantial amendment** (avg 3.3)

~$2.1M
in **direct cost** & **3 months** *unplanned* delay **per amendment**

Before you file your IND — *know if your trial will work.*

Step 01

You Share Your Asset Profile

Step 02

We Map It Against Translational Ground Truth

Step 03

We Simulate the Clinical Scenarios

Step 04

You get documented evidence to support your Pre-IND decision

Asset Feasibility Snapshot

- 30 minutes, one asset
- Written summary of your translational risk signals
- Specific questions to answer

Gabrielle Foster

Founder

Former Takeda R&D Clinical Operations leader;

MIT trained data scientist;

MPH/MSPH;

Doctoral researcher in AI-enabled clinical trials.

gabrielle@fosterrx.com

www.fosterrx.com

alzheimer's association®

Business Consortium

Advancing Alzheimer's Research with AI Powered Digital Health Technologies

Bryan Hansen, PhD
Neuroscience & Digital Health Leader
Former Merck & J&J Executive

Advancing Alzheimer's Research with AI-Powered Digital Health Technologies

Bryan J. Hansen, PhD

Neuroscience & Digital Health Leader

Former Merck & J&J Executive

February 25, 2026

Alzheimer's Association Business Consortium

Alzheimer's Diseases: Unmet Medical Need and Societal Burden



Between 2000 and 2019, deaths from heart disease decreased 7.3% while deaths from AD have **increased 145%**

In 2020, caregivers provided an estimated **15.3 billion hours** of care valued at nearly $257 billion

Neurodegenerative processes occur up to **20 years before** symptoms begin to show.

Disease progression is **inherently variable**, and traditional tests are inconvenient and less reliable.

In the United States, AD and dementia deaths have **increased 16%** during the COVID-19 pandemic.

https://www.alz.org/alzheimers-dementia/facts-figures

The Challenge with Alzheimer's Trials

What if trials are failing not because the drugs don't work?

Late Detection

By the time memory impairment is clinically visible, significant neurodegeneration has already occurred, limiting disease-modifying options.

Noisy Clinical Endpoints

Traditional assessments are episodic, subjective, and sensitive to subtle changes, making it difficult to detect early therapeutic effects.

Trial Recruitment Bottlenecks

Identifying biomarker-confirmed, early-stage participants is time-consuming and expensive, often delaying enrollment and extending trial timelines.

Costly Biomarker Tools

Gold-standard diagnostics like amyloid PET and cerebrospinal fluid analysis are invasive, costly, and hard to scale.

Fundamental Definition of ~~Digital Biomarkers~~ Digital Phenotyping

Objective, quantifiable measurements of biological processes that reflect physiological responses to disease progression or therapeutic intervention collected using a digital device and analyzed using AI.

Clinical Endpoint



Active





Passive





Moore et al., 2025; These are just a few examples of the technologies and not an endorsement of any product

Early Detection and Continuous Monitoring Using a Multi-Modal Cognitive Assessment





Multimodal sensor capture
Combines motion, speech/language, AR interaction, and touch for deep insights of performance.

High-precision disease capture
One test quantifies subtle, meaningful change with a validated composite score, enabling smarter screening, stratification, and monitoring.

Built for scale: In-clinic or at-home
Self-administered ideal for decentralized trials and continuous monitoring across sites and phases.

Hassenstab et al., 2017; Muurling et al., 2023; Au et al., 2025

Augmented Reality Detects Early Alzheimer's Earlier Than Standard Tests

The Digital NeuroMarker Platform (Altoida) distinguishes healthy controls (HC) from those with preclinical (Pre) and prodromal (Pro) AD in both clinic and at-home settings, a capability that standard cognitive tests lack.





AR Task:
Participants navigate their room to place and find virtual objects during a 3D augmented reality experience.

Muurling et al., 2023

Multimodal Digital Phenotyping: A Strategic Multiplier



Patient Identification

- Continuous behavioral + cognitive data enables earlier risk stratification
- **Accelerates commercial ramp-up** through precision targeting

Earlier & Richer Signal Detection

- Integrates speech, mobility, and cognition
- Reduces uncertainty in both trials and post-market use

Real-World Evidence Drives Access

- Longitudinal, at-home functional data
- **Enables indication expansion** with post-launch evidence loops

Muurling et al., 2023

Digital Health for Aging Populations

Earlier Intervention

Intervening during preclinical or prodromal stages offers the best chance to slow or prevent neurodegeneration.

Real-world evidence

Supports continuous learning cycles that improve patient selection, treatment methods, and outcome assessment.

AI-Enabled Biomarkers

Integrating multimodal behavioral and physiological data, GenAI can identify new biomarkers and create realistic digital twins.



Chen et al., 2023

Bryan J. Hansen, PhD

Contact Information:
E: bryanjhansenphd@gmail.com
LinkedIn

The future of Alzheimer's research is not episodic.

It is continuous.

It is computational.

And it starts earlier than we think.

alzheimer's association®

Business Consortium

AI: Accelerating & Securing Parterships

Roxanne Alaniz
Founder & CEO Alaniz Health

AI: ACCELERATING AND SECURING PARTNERSHIPS

The Commercial Intelligence Engine

Roxanne Alaniz | Alzheimer's Business Consortium

ALANIZ HEALTH

THE ENTERPRISE GAP

Innovation vs. Infrastructure

- Big Pharma has 1000+ Person Sales Teams.
- You have Innovation. You need the Reach.
- How do you bridge the gap without the overhead?

VS

AI is the Bridge

THE TECHNOLOGY SHIFT



From "Demographics" to "Signals"

Beyond Simple AI

It's not just "Writing Emails."

It is "Orchestrating Intelligence."

THE ENGINE ARCHITECTURE

Alaniz AI Engine Commercial Intelligence

Multi-Source Waterfalling
(Aggregating 100’s Databases).

Identity Resolution
(Real-Time Verification).

Behavioral Scoring
(Detecting Buying Signals).



"Waterfall Enrichment" → "Behavioral Scoring."

THE SIGNAL ADVANTAGE

Timing is Everything.



Don't reach out because they "Exist."

Reach out because they "Signaled."

Example: "Just hired VP of Clinical Ops" = Signal.

INSTANT COMMERCIAL SCALE

We Built the Infrastructure.
You Get the Meetings.



FREE PARTNERSHIP SIGNAL AUDIT

See Who Is Looking For You Right Now.

1. Give us your Top 3 Partners
2. We run a Signal Scan.
3. Develop a list of Actively Looking Buyers for Your Solution

https://www.alanizmarketing.com/aabc/

Roxanne Alaniz

CEO Alaniz Health & Alaniz Marketing

Phone: 415-892-5252

Roxanne@alanizmarketing.com

https://alaniz.health